🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for PD-L1 Gene Mutation

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site📍 Wuxi Wuxi People's Hospital · Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites📍 Guangzhou📍 Shanghai Ruijin Hospital · Tests: Toripalimab A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC NCT07807163Phase 27 sites📍 Fort Myers📍 Orlando📍 St. Petersburg Bicara Therapeutics · Tests: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis NCT06501391Phase 21 site📍 Shanghai Fudan University · Tests: PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% NCT07279402n/a25 sites📍 Adana📍 Afyonkarahisar📍 Ankara Antalya Training and Research Hospital The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581Phase 3416 sites📍 Huntsville📍 Gilbert📍 Phoenix Eli Lilly and Company · Tests: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients NCT07618936n/a3 sites📍 Hefei📍 Qingdao📍 Tianjin Tianjin Medical University · Tests: Single Group Assignment
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy